Immuno-Oncology Landscape

Landscape of Immuno-Oncology Drug Development

With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.

We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication.

 

A comparison of global IO pipelines in 2017 and 2020. 4,720 immuno-oncology agents in six main classes were identified in August 2020, an increase of 233% since 2017. More details can be found in the Nature Reviews Drug Discovery article.

IO Landscapes Publications

Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets. 

The most recent overview immuno-oncology landscape publication is “Immuno-oncology drug development forges on despite COVID-19. ” in Nature Reviews Drug Discovery (September 2020).

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us

IO Landscapes

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.